When it comes to the fight against cancer, there are many individuals who are doing their best to eradicate this deadly disease. Over the past decade, there have been many advancements in cancer research and Dr. Clay Siegall stands at the forefront. Dr. Siegall is the CEO and the president of Seattle Genetics. This company specializes in developing and commercializing antibody-based therapies. These therapies are some of the most innovative medications thanks to their progressive capabilities. ADCETRIS, the company’s premier medication, produces great results as it attacks cancerous cells within the body while sparing the good cells. As of today, ADCETRIS has generated over $350 million in revenue for Seattle Genetics. The company has grown so fast that its stock has nearly tripled over the past few years.
Dr. Clay Siegall is the captain of the ship, and he has many years of experience from working in the industry. With a Ph.D in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland, Dr. Siegall is very well overqualified. His passion, expertise and perseverance has revolutionized the industry from the inside out. He has worked with many of the biggest names in the business. This includes:
- The National Institute of Health
- Bristol Myers Squibb
- The National Cancer Institute
Since its inception, Seattle Genetics has grown in size and in stature. The company is located in Bothell, Washington, and it employs over 1,000 individuals. The company has a solid foundation. It prides itself on scientific innovation, drug development and rigorous research. Dr. Siegall is showing no signs of slowing down because every life counts. Cancer hits home for Siegall as he once had to watch his father struggle with the disease until his death. The fire inside of this guy is burning hot, and he won’t stop until every person is healed.